NCT00546754View on ClinicalTrials.gov

BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)

PHASE3CompletedINTERVENTIONAL

Enrollment

808

Participants

Timeline

Start Date

May 1, 2007

Primary Completion Date

April 1, 2009

Study Completion Date

May 1, 2009

Conditions

Hypertension

Interventions

DRUG

losartan potassium (+) hydrochlorothiazide

losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide

DRUG

Comparator: Valsartan (+) Hydrochlorothiazide

Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00546754 - BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) | Biotech Hunter | Biotech Hunter